Xeltis’ aXess graft demonstrated high patency rates and no infections after six months in the first-in-human trial.

Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.

LSP says its new fund for medical device and drug development companies will be the biggest fund dedicated to life sciences companies in Europe.

Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology.